In Vitro Evaluation of Antibacterial Activity of A Novel Polyenzyme Preparation Immunoseb

Novel polyenzyme formulations which are proprietary blends of different enzymes such as bromelain, papain, acid and alkaline proteases, serratiopeptidase, lysozyme etc. have been developed by Advanced Enzyme Technologies Ltd., Thane and Specialty Enzymes Co. USA, group of Companies, Screening for antibacterial activity of Immunoseb, a novel polyenzyme formulation under development, was done using ATCC strains and clinical isolates of Salmonella typhi, Pseudomonas aeruginosa, E. coli, Staphylococcus aureus, Streptococcus pyogenes and S. pneumoniae employing a modified antibiotic susceptibility test. The polyenzyme formulation was found to have activity against P. aeruginosa S. aureus, S. pyogenes and S. pneumoniae at the test concentration. Synergistic effect was established when Immunoseb was used in conjunction with Ampicillin against E. coli and with Penicillin against Streptococcus pyogenes. Partial synergy was established when it was used in conjunction with Ceftazidime against Pseudomonas aeruginosa and with Ciprofloxacin against Salmonella typhi. Antagonism was established when it was used in combination with Ceftazidime against S. typhi and with Ciprofloxacin against both, coagulase negative staphylococcal strain and Staphylococcus aureus. Immunoseb has antibacterial activity against some commonly encountered pathogens and therefore has the potential of being a novel broad range antibacterial drug. It can be used in conjunction with those antibiotics with which a synergistic effect or partial synergy could be demonstrated since their MIC levels could be decreased. Thus they appear to have good potential as potentiators of currently used antibiotics. In cases where antagonism was established, it should not be used in combination with that particular antibiotic.